Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer: a prospective blinded comparative study in Japan.
Takahiro KojimaHiroyuki NishiyamaSeiichiro OzonoShiro HinotsuNaoto KeinoAkito YamaguchiHideki SakaiYutaka EnomotoShigeo HorieKiyohide FujimotoHideyasu MatsuyamaTakehiko OkamuraYusuke KanimotoMototsugu OyaNorio NonomuraSeiji NaitoHideyuki AkazaPublished in: International journal of clinical oncology (2018)
The UroVysion test provided higher sensitivity than urine cytology to detect bladder cancer during post-TURBT follow-up. Two consecutive UroVysion tests might be a better indicator to predict intravesical recurrence.